One of the promoter group has exited the business and has been selling in the open market. I don’t think Advenza can directly compete with AETL. Mgmt. had informed the same in one of the concalls. Also, enzyme is a high-entry barrier business with a long gestation period, product testing and approvals, switching costs, and a long customer acquisition cycle. A significant concern that persists, however, is the lack of growth, which has been elusive for the past few quarters.
Disc: Biased. Invested in self, family, and client accounts.
| Subscribe To Our Free Newsletter |
